Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideFRA:FQ2 -6.03%31 Return-on-Tangible-Equity is 16.52% as of Dec. 2025, which is 65% below its 10-year median of 46.61. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100. Among 1,199 Biotechnology companies, Medtide ranks better than 86.82% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medtide's annualized net income for the quarter that ended in Dec. 2025 was €27.98 Mil. Medtide's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €169.35 Mil. Therefore, Medtide's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 16.52%.
The historical rank and industry rank for Medtide's Return-on-Tangible-Equity or its related term are showing as below:
FRA:FQ2'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.78 Med: 46.61 Max: 882
Current: 11.78
During the past 5 years, Medtide's highest Return-on-Tangible-Equity was 882.00%. The lowest was 11.78%. And the median was 46.61%.
FRA:FQ2's Return-on-Tangible-Equity is ranked better than 86.82% of 1199
companies
in the Biotechnology industry
Industry Median: -40.99
vs FRA:FQ2: 11.78
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medtide Return-on-Tangible-Equity Related Terms
Medtide Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medtide's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FQ2 vs VRTX, REGN, MRNA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Medtide's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medtide's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.52% mean?
Medtide (FRA:FQ2) has a Return-on-Tangible-Equity of 16.52% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medtide and its competitors. This is 65% below median its historical median of 46.61. Over the past decade, Medtide's Return-on-Tangible-Equity has ranged from 11.78 to 882.00. According to the industry distribution chart, Medtide ranks #158 out of 1199 companies in the Biotechnology industry, placing it in the top 13.2%.
Is Medtide's Return-on-Tangible-Equity too high?
Medtide's current Return-on-Tangible-Equity of 16.52% is 65% below median its 10-year median of 46.61. Over the past 10 years, this metric has ranged from a low of 11.78 to a high of 882.00. Based on the distribution chart, Medtide ranks #158 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #158 out of 1199 companies for Return-on-Tangible-Equity. This places Medtide in the top 13% of its industry — outperforming the majority of peers. Historically, Medtide's own Return-on-Tangible-Equity has ranged from 11.78 to 882.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medtide and its competitors. Medtide's current Return-on-Tangible-Equity is 16.52%, which is 65% below median its own 10-year median of 46.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current Return-on-Tangible-Equity of 16.52%. The current Return-on-Tangible-Equity is 16.52%, which is 65% below median its 10-year median of 46.61. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current Return-on-Tangible-Equity is 16.52% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score
Get the complete analysis for FRA:FQ2
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FQ2 has been successfully added to your 
